Fablyn

Treatment for Osteoporosis

Pfizer Statement on Lasofoxifene

NEW YORK, September 13, 2005 -- Pfizer Inc said today it has received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis.

Pfizer said that it will be reviewing its submission with the FDA and considering various possible courses of action.

Source: Pfizer Inc





Posted: September 2005

Related Articles

Fablyn (lasofoxifene tartrate) FDA Approval History

View comments

Hide
(web2)